Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Metabolic SyndromeHypertension
Interventions
DRUG

Irbesartan

Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.

DRUG

Hydrochlorothiazide

Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.

Trial Locations (25)

Unknown

Local Institution, Angers

Local Institution, Nantes

Local Institution, Tiercé

Local Institution, Hanover

Local Institution, München

Local Institution, Ornbau

Local Institution, Rotenburg An de Fluda

Local Institution, Tübingen

Local Institution, Villingen-Schwenningen

Local Institution, Ancona

Local Institution, Chieti Scalo

Local Institution, Pisa

Local Institution, Ravenna

Local Institution, Sassari

Local Institution, Oslo

Local Institution, Snaroya

Local Institution, Moscow

Local Institution, Saint Petersburg

Local Institution, Saratov

Local Institution, Yaroslavl

Local Institution, A Coruña

Local Institution, Barcelona

Local Institution, Granada

Local Institution, Seville

Local Institution, Zaragoza

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY